SCHEMBL23364852

SCHEMBL23364852

COC(=O)C1CCC(c2cccc(OCc3ccccc3)c2)C1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.51
MAOB P27338 2/20 0.48
ADAM17 P78536 2/20 0.47
KDM1A O60341 1/20 0.47
NR4A2 P43354 1/20 0.47
SMPD1 P17405 1/20 0.46
FAAH O00519 1/20 0.46
CNR2 P34972 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
HIF1A Q16665 1/20 0.45
HDAC4 P56524 1/20 0.45
AKR1C3 P42330 1/20 0.45
AKR1C1 Q04828 1/20 0.45
PTPN1 P18031 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KDM2B Q8NHM5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23364692 0.89 MAOB (0.52) KCNH2MAOBADAM17KDM1ANR4A2
SCHEMBL23364637 0.89 AKR1C3 (0.58) KCNH2MAOBKDM1ANR4A2SMPD1
SCHEMBL23364714 0.86 KCNH2 (0.47) KCNH2MAOBADAM17KDM1ANR4A2
SCHEMBL15091694 0.81 KDM1A (0.52) KCNH2MAOBADAM17KDM1ANR4A2
SCHEMBL15091696 0.81 KDM1A (0.52) KCNH2MAOBADAM17KDM1ANR4A2
SCHEMBL6583019 0.81 MAOB (0.56) KCNH2MAOBKDM1ANR4A2MRGPRX4
SCHEMBL23380025 0.81 KDM1A (0.48) KCNH2MAOBKDM1ANR4A2
SCHEMBL29932805 0.81 MAOB (0.50) KCNH2MAOBADAM17KDM1ANR4A2
SCHEMBL7098576 0.81 MAOB (0.50) KCNH2MAOBADAM17KDM1ANR4A2
SCHEMBL23364576 0.80 CYSLTR2 (0.53) KCNH2MAOBKDM1ANR4A2SMPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025129104-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS INC. (US) 2025-06-19 WO disclosed
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION 2024-01-04 US disclosed
EP-4058439-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY Genzyme Corporation (US) 2022-09-21 EP disclosed
CN-115003659-A 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity 健赞公司 2022-09-02 CN disclosed
WO-2021097057-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY CFTR, PKD2, PKD1 KCNH2 549/4885MAOB 3591/4885ADAM17 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.